Where we lead, the
future follows

Taylor Harris has led Cutera as CEO since August 2023. Mr. Harris served as the Chief Financial Officer for MyoKardia, Inc., from April 2018 until that company’s acquisition by Bristol Myers Squibb in November 2020. Prior to that, Mr. Harris served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., until that company’s acquisition by Allergan plc. He also served as Vice President and Chief Financial Officer at Thoratec Corporation, which was eventually acquired by St. Jude Medical, Inc., and worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a Vice President in the firm’s Healthcare Investment Banking and Equity Research departments. Mr. Harris currently serves on the board of PROCEPT BioRobotics, Omada Health, and Endologix. He previously served on the board of HealthCor Catalio Acquisition Corp. Mr. Harris holds a bachelor’s degree from the University of North Carolina at Chapel Hill.

Stuart Drummond has served as the Cutera Vice President and Corporate Controller since July 2021. From November 2019 until June 2021, he served as Senior Director, Corporate Controller at Sangamo Therapeutics, Inc., and from July 2016 to March 2019 he served as Corporate Controller of CareDx, Inc. Mr. Drummond earned his bachelor’s degree from Otago University, New Zealand, and graduate accounting qualification from Victoria University, New Zealand. Mr. Drummond obtained his Chartered Accounting certification in New Zealand with KPMG.

Jeff Jones is responsible for end-to-end operations, including manufacturing, quality, supply chain and field service engineering at Cutera. He has served for over three decades in senior operational leadership roles at medical device companies including Sientra Inc., Earlens Inc., Benvenue Medical Inc., Acclarent Inc./Johnson & Johnson, Reliant Technologies Inc., Lumend Inc., EP Technologies / Boston Scientific Corporation and Coherent Medical Group. Mr. Jones holds a bachelor’s degree in Engineering from the U.S. Military Academy at West Point and an M.B.A. from Golden Gate University.

Stephana brings over 25 years of experience creating portfolio value at private and publicly-traded medical device, biotechnology and pharmaceutical companies. She joined us in October 2023 as our Chief Legal Officer and she provides leadership of our legal, HR, Regulatory and Medical Affairs teams. She was formerly the Chief Legal Officer, Corporate Secretary and Chief Compliance Officer at InterVenn Biosciences, life science company unlocking the value of glycoproteomics to develop transformational healthcare solutions. Prior to that, she was the General Counsel, Corporate Secretary, and Chief Compliance Officer of Eiger BioPharmaceuticals, Inc., a commercial stage biopharmaceutical company focused on developing therapies for rare and ultra-rare diseases. Prior to Eiger, she was the General Counsel, Corporate Secretary, and Chief Compliance Officer of BioTime, Inc., a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases.

Prior to BioTime, she was the General Counsel and Commercial Compliance Officer at BioDelivery Sciences, a publicly traded specialty pharmaceutical company. Before BDSI, she held various senior management positions, including leading Intellectual Property (IP) and Licensing at Salix Pharmaceuticals, a global pharmaceutical company that was acquired for $11.2 billion in 2015. Prior to joining Salix, Dr. Patton was in private practice at a large international law firm known for its IP and corporate securities practices. Her practice focused on counseling clients on IP-related matters as well as licensing transactions for biotechnology and pharmaceutical companies at varying stages of product development. Dr. Patton earned a J.D. from the Boston University School of Law, and a Ph.D. in Biochemistry, Cell, and Developmental Biology from Emory University.

Steve Kreider has served as Senior Vice President, Global Marketing at Cutera since January 2022. Mr. Kreider has spent nearly 20 years in the dermatology market, holding leadership roles in marketing, sales, and business development. He was previously VP of Sales for Ortho Dermatologics and led North American marketing for Merz Aesthetics’ Ulthera (aesthetic device) division. Mr. Kreider began his career in dermatology and aesthetics at Medicis.  He earned his bachelor’s degree from Muhlenberg College.

Cutera President, International, Brent Hauser, has over two decades of aesthetics industry experience in commercial roles of increasing responsibility. Mr. Hauser started his career in the laser aesthetics industry at Solta Medical, where he held sales leadership positions in both the European and Asia Pacific regions. Subsequently, Mr. Hauser joined Zeltiq, where he rose to the position of President, North American Operations, responsible for all commercial activity in North America. Following the acquisition of Zeltiq by Allergan, Mr. Hauser became Vice President of Sales and Marketing for the CoolSculpting brand on a global basis. In the previous two years, Mr. Hauser served as Senior Vice President of Global Sales for InBrace. Mr. Hauser holds a bachelor’s degree in Biology from Stanford University, where he was an All-American cross country runner, holding several school records. He currently serves on the board of directors of the Cure JM (juvenile myositis) Foundation.

Lukas Hunziker leads Cutera’s engineering and clinical research groups. He has over 20 years of experience developing laser, radio frequency, and ultrasound technologies for applications in dermatology, ophthalmology, biotechnology, and telecom. Lukas joined Cutera in 2008 as Director of Advanced Research and currently serves as Senior Vice President of R&D. He started his career at the Medical Division of Coherent, where he developed multiple laser systems for laser eye surgery. Prior to joining Cutera, he also worked at Coherent’s Laser Division, Lumentum, Viavi, and SRI International in various technical leadership and engineering management roles.

Lukas received a B.S. in Chemistry from U.C. Davis and a Ph.D. in Physical Chemistry from U.C. Berkeley, where his research focused on the development of femtosecond lasers and time-domain laser spectroscopies.